Core Viewpoint - Akso Health Group has launched an exploratory patient support program in collaboration with Nanning Duoling Research Institute, aiming to provide free in-hospital treatment plans for up to 10,000 eligible cancer patients, integrating Traditional Chinese Medicine with modern medical technology [1][2]. Group 1: Patient Support Program - The program will coordinate medical resources to address the urgent needs of cancer patients, promoting "global resource integration + zero-cost access" [1]. - The initiative aims to create a closed-loop model of "global resource connection + local technology landing + full-cycle patient service," focusing on "zero-cost full-chain coverage" to alleviate high medical costs and improve access to care for over 20 million new cancer patients globally, including 4.06 million new cases annually in China [2]. Group 2: Strategic Cooperation - Under the strategic cooperation framework, Nanning Duoling will provide exclusive cancer diagnosis and treatment technologies, along with a professional laboratory testing system and expert teams [2]. - The collaboration seeks to explore a framework for integrating third-party medical resources through licensed institutions, ensuring compliance with medical regulations [3]. Group 3: Implementation and Evaluation - The company emphasizes the importance of responsibly evaluating healthcare implementation models within real-world systems, aiming for sustainable and compliant healthcare accessibility [5]. - The initiative is in its early stages, with a cautious approach to assess scalability and feasibility while maintaining a clear separation between corporate activities and regulated medical services [4][5]. Group 4: Company Background - Akso Health Group, formerly known as Xiaobai Maimai Inc., has transitioned from e-commerce to healthcare services, specializing in medical device sales in China and the U.S., and has acquired interests in online medical consultation services [7].